AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19762734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL/kg of 0.225% ropivacaine (low volume/high concentration, LVHC)
Number of subjects: 73
Study 17556779 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12-week home-based)
Number of subjects: 31
Study 15551194 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA) 5-20 mg/d
Number of subjects: 28
Study 15551194 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol (FLU) 5-20 mg/d
Number of subjects: 28
Study 10658681 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 + G-CSF mobilization
Number of subjects: 43
Study 10658681 — intervention group
Group type: COMPARATOR
Intervention: G-CSF mobilization alone (Control)
Number of subjects: 43
Study 9281930 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed verbal prompts and positive reinforcement during nine consecutive meals
Number of subjects: 24
Study 9281930 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 24
Study 1313459 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate-containing dentifrice (SCH) with one abrasive system
Number of subjects: 40
Study 1313459 — intervention group
Group type: COMPARATOR
Intervention: Strontium chloride hexahydrate-containing dentifrice (SCH) with another abrasive system
Number of subjects: 40
Study 3935466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (Nitroderm TTS 5)
Number of subjects: 10
Study 3935466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31368191 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 52
Study 31368191 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (D5W)
Number of subjects: 52
Study 29117472 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (weekly messages for 22 weeks) in addition to healthy lifestyle counselling
Number of subjects: 30
Study 29117472 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 30
Study 29117472 — intervention group
Group type: COMPARATOR
Intervention: Control group (counselling on healthy diet and exercise)
Number of subjects: 30
Study 29117472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26452978 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified papilla preservation flap (SPPF) with guided tissue regeneration (GTR)
Number of subjects: 18
Study 26452978 — intervention group
Group type: COMPARATOR
Intervention: Simplified papilla preservation flap (SPPF) without guided tissue regeneration (GTR)
Number of subjects: 18
Study 26452978 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 18
Study 25220877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast blood sampling (40 seconds)
Number of subjects: 20
Study 25220877 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow blood sampling (70 seconds)
Number of subjects: 20
Study 22760109 — intervention group
Group type: EXPERIMENTAL
Intervention: SWEET (bilevel cycle ergometry endurance exercise training)
Number of subjects: 24
Study 22760109 — intervention group
Group type: COMPARATOR
Intervention: OxCar (walking while pushing an OxCar and traditional diaphragmatic breathing)
Number of subjects: 24
Study 21046932 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of OROS hydromorphone once daily
Number of subjects: 30
Study 21046932 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of immediate-release hydromorphone four times daily
Number of subjects: 30
Study 21046932 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 18561878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy
Number of subjects: 200
Study 18561878 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 16525182 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, photodynamic therapy
Number of subjects: 0
Study 16525182 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery of chemotherapy
Number of subjects: 0
Study 16525182 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 16525182 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental therapies such as immunotherapy
Number of subjects: 0
Study 12411282 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 0.12, 0.9, or 7% saline
Number of subjects: 16
Study 12411282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with amiloride followed by inhalation of 0.12 and 0.9% saline
Number of subjects: 16
Study 12411282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with amiloride and inhalation of 7% saline
Number of subjects: 16
Study 12411282 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of vehicle (0.12% saline)
Number of subjects: 16
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and foot protection programme
Number of subjects: 69
Study 11074391 — intervention group
Group type: COMPARATOR
Intervention: Special footwear
Number of subjects: 69
Study 11074391 — intervention group
Group type: COMPARATOR
Intervention: Educational programmes
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatric care
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Total contact casting
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical growth factors (particularly platelet-derived growth factor)
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketanserin
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hyperbaric oxygen therapy
Number of subjects: 69
Study 11074391 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost and prostaglandin E1 (PGE1)
Number of subjects: 69
Study 8975251 — intervention group
Group type: EXPERIMENTAL
Intervention: newly developed film‐coated tablet with sustained release
Number of subjects: 24
Study 8975251 — intervention group
Group type: COMPARATOR
Intervention: reference formulation
Number of subjects: 24
Study 1310572 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet induction therapy at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days.
Number of subjects: 0
Study 1310572 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet maintenance therapy at a dosage of 90 mg/kg/day via 2-hour infusion.
Number of subjects: 0
Study 1310572 — intervention group
Group type: COMPARATOR
Intervention: Foscarnet treatment delayed until the first signs of retinitis progression (Control group).
Number of subjects: 0
Study 7398735 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated digoxin capsules (0.38 mg)
Number of subjects: 8
Study 7398735 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablets (ultrarapidly dissolving)
Number of subjects: 8
Study 31444589 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg enfortumab vedotin (Arm A)
Number of subjects: 17
Study 31444589 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg enfortumab vedotin (Arm B)
Number of subjects: 17
Study 31444589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of enfortumab vedotin
Number of subjects: 17
Study 31464638 — intervention group
Group type: EXPERIMENTAL
Intervention: STan (cardiotocographic electronic fetal monitoring plus ST segment analysis)
Number of subjects: 1818
Study 31464638 — intervention group
Group type: COMPARATOR
Intervention: CTG alone (cardiotocography monitoring)
Number of subjects: 1818
Study 29182706 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg BID tramiprosate
Number of subjects: 147
Study 25630874 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Number of subjects: 26
Study 25011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with schizophrenia
Number of subjects: 90
Study 25011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with localized frontal lobe lesions
Number of subjects: 90
Study 25011237 — intervention group
Group type: COMPARATOR
Intervention: Healthy men (control group)
Number of subjects: 90
Study 21857489 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral suppression group (initiated ART)
Number of subjects: 254
Study 21857489 — intervention group
Group type: COMPARATOR
Intervention: Drug conservation group (deferred ART)
Number of subjects: 254
Study 19689568 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Training Programme supplemented by a curriculum unit on social and emotional skills
Number of subjects: 15
Study 18254574 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone oral solution + placebo tablets + procaterol MDI
Number of subjects: 43
Study 18254574 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone tablets + placebo oral solution + procaterol MDI
Number of subjects: 43
Study 16311201 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial weight bearing (200 N)
Number of subjects: 34
Study 16311201 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 34
Study 16311201 — intervention group
Group type: EXPERIMENTAL
Intervention: Force time integrals (impulses transferred to the ground)
Number of subjects: 34
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.3 mg)
Number of subjects: 77
Study 14568892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10736933 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphurous‐arsenical‐ferruginous water (group A)
Number of subjects: 37
Study 10736933 — intervention group
Group type: COMPARATOR
Intervention: drinking water from the city mains (group B)
Number of subjects: 37
Study 8833634 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (patients set their own priorities)
Number of subjects: 40
Study 8833634 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (DSN set educational priorities)
Number of subjects: 40
Study 2097565 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d. e.v.) starting from the day before the operation and continuing for the following seven days
Number of subjects: 100
Study 2097565 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (5,000 IU b.i.d. by s.c. route) from day 0 to the 7th post-operative day
Number of subjects: 100
Study 6252780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 33
Study 6252780 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 33
Study 6252780 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 33
Study 31912787 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen gloves (FGs) worn on both hands during chemotherapy
Number of subjects: 180
Study 31912787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not wearing FGs)
Number of subjects: 180
Study 29532440 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) extended-release capsules, administered orally once daily at bedtime.
Number of subjects: 196
Study 29532440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 27626255 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombovasim® 1,600 IU
Number of subjects: 154
Study 27626255 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombovasim® 3,200 IU
Number of subjects: 154
Study 27626255 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombovasim® 4,800 IU
Number of subjects: 154
Study 27626255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 24310580 — intervention group
Group type: COMPARATOR
Intervention: Conventional liposuction with abdominoplasty
Number of subjects: 36
Study 24310580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of conventional and laser-assisted liposuction with abdominoplasty
Number of subjects: 36
Study 24310580 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted liposuction with abdominoplasty
Number of subjects: 36
Study 22720764 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 928
Study 22720764 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 928
Study 19948568 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM) intervention
Number of subjects: 48
Study 19948568 — intervention group
Group type: COMPARATOR
Intervention: Community intervention (control)
Number of subjects: 48
Study 19091759 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitations timed in the week of their birthday or assigned to screening in the first or second week after their birthday
Number of subjects: 12960
Study 19091759 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitations timed in December
Number of subjects: 12960
Study 19091759 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attendance improvement
Number of subjects: 12960
Study 15823447 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 18 microg + formoterol 12 microg
Number of subjects: 20
Study 15823447 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + tiotropium 18 microg
Number of subjects: 20
Study 12433894 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty with optional stenting
Number of subjects: 181
Study 10608394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg MultiHance
Number of subjects: 120
Study 10608394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg MultiHance
Number of subjects: 120
Study 10608394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg and 0.2 mmol/kg MultiHance
Number of subjects: 120
Study 7795829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal diet (high in fruits, vegetables, whole cereal products, low-fat dairy, fish, chicken, and lean meats)
Number of subjects: 456
Study 7795829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet (high in potassium, magnesium, and dietary fiber)
Number of subjects: 456
Study 7795829 — intervention group
Group type: COMPARATOR
Intervention: Control dietary pattern (low in potassium, magnesium, calcium, and fiber)
Number of subjects: 456
Study 2393206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg four times daily for 2 days
Number of subjects: 13
Study 2393206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2393206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 13
Study 7032370 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal solution (300 micrograms/day)
Number of subjects: 20
Study 7032370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31846189 — intervention group
Group type: EXPERIMENTAL
Intervention: RJ101
Number of subjects: 59
Study 31846189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31204294 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-dosed heavy-slow resistance training program
Number of subjects: 70
Study 31204294 — intervention group
Group type: COMPARATOR
Intervention: Pre-determined heavy-slow resistance training program
Number of subjects: 70
Study 28068956 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam monotherapy
Number of subjects: 2283
Study 28068956 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam/macrolide combination
Number of subjects: 2283
Study 28068956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone monotherapy
Number of subjects: 2283
Study 25788197 — intervention group
Group type: COMPARATOR
Intervention: LAM 100 mg daily
Number of subjects: 70
Study 25788197 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF 10 mg daily
Number of subjects: 70
Study 23098358 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy practice (task-oriented approach)
Number of subjects: 46
Study 21414565 — intervention group
Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine/HCTZ (300/10/25 mg)
Number of subjects: 412
Study 21414565 — intervention group
Group type: COMPARATOR
Intervention: aliskiren/amlodipine (300/10 mg)
Number of subjects: 412
Study 19153265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 465
Study 19153265 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 465
Study 19153265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aliskiren and Losartan
Number of subjects: 465
Study 17397702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 41
Study 17397702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal electroanalgesia (TSE)
Number of subjects: 41
Study 17397702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham TSE)
Number of subjects: 41
Study 15226274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow‐Lyon product criterion
Number of subjects: 348
Study 15226274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell criterion
Number of subjects: 348
Study 15226274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell product criteria
Number of subjects: 348
Study 15226274 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG LVH criteria
Number of subjects: 348
Study 15226274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell and Cornell product criteria
Number of subjects: 348
Study 10968732 — intervention group
Group type: COMPARATOR
Intervention: Control diet (1,200 to 1,500 kcal/d) - Group A
Number of subjects: 100
Study 10968732 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic diet with meal and snack replacements - Group B
Number of subjects: 100
Study 9063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered HSA charcoal (2,000 m2/g)
Number of subjects: 6
Study 9063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular HSA charcoal
Number of subjects: 6
Study 9063541 — intervention group
Group type: COMPARATOR
Intervention: Low-surface-area (LSA) charcoal (950 m2/g)
Number of subjects: 6
Study 9063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Total AUC for the 5-hour study period with powdered HSA charcoal
Number of subjects: 6
Study 9063541 — intervention group
Group type: EXPERIMENTAL
Intervention: Total AUC for the 5-hour study period with granular HSA charcoal
Number of subjects: 6
Study 8095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 3 ng min-1kg-1
Number of subjects: 18
Study 8095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 6 ng min-1kg-1
Number of subjects: 18
Study 8095006 — intervention group
Group type: COMPARATOR
Intervention: Octreotide pretreatment (0.8 microgram/kg subcutaneously) before insulin infusion
Number of subjects: 18
Study 8095006 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion during hypoglycaemia
Number of subjects: 18
Study 3757767 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent methadone delivery (N = 13)
Number of subjects: 39
Study 3757767 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contingent methadone delivery (N = 13)
Number of subjects: 39
Study 3757767 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 13)
Number of subjects: 39
Study 3757767 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent methadone delivery
Number of subjects: 39
Study 31615489 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer evaluation system (intervention group)
Number of subjects: 223
Study 31615489 — intervention group
Group type: COMPARATOR
Intervention: Standard team project approach (control group)
Number of subjects: 223
Study 29148074 — intervention group
Group type: EXPERIMENTAL
Intervention: Salutogenic Healthy Ageing Programme Embracement (SHAPE)
Number of subjects: 154
Study 29148074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 26757788 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3015014 300 mg every 4 weeks (Q4W)
Number of subjects: 527
Study 26757788 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3015014 300 mg every 8 weeks (Q8W)
Number of subjects: 527
Study 26757788 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 527
Study 24119318 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle intervention consisting of aerobic and resistance exercise with parallel dietary advice
Number of subjects: 100
Study 24119318 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 100
Study 22453654 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 712
Study 22453654 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study 20500784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year group leisure programme
Number of subjects: 37
Study 20500784 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 37
Study 17466520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid spinal orthosis
Number of subjects: 21
Study 17466520 — intervention group
Group type: EXPERIMENTAL
Intervention: SpineCor (flexible spinal orthosis)
Number of subjects: 21
Study 15866953 — intervention group
Group type: EXPERIMENTAL
Intervention: Teno Fix
Number of subjects: 67
Study 15866953 — intervention group
Group type: COMPARATOR
Intervention: Suture repair (control)
Number of subjects: 67
Study 12648985 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 136